Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
501449
Reference Type
Journal Article
Title
Hyponatremia and arginine vasopressin dysregulation: Mechanisms, clinical consequences, and management
Author(s)
Miller, M
Year
2006
Is Peer Reviewed?
1
Journal
Journal of the American Geriatrics Society
ISSN:
0002-8614
EISSN:
1532-5415
Volume
54
Issue
2
Page Numbers
345-353
Language
English
DOI
10.1111/j.1532-5415.2005.00609.x
Abstract
Hyponatremia, the most common electrolyte disorder, occurs frequently in older people and in hospitalized patients. Physiological changes of aging that interact with diseases and drugs commonly present in older people put this population at greater risk for hyponatremia. It can accompany central nervous system disorders, pulmonary and renal disease, cancer, congestive heart failure, and liver cirrhosis, as well as many commonly used drugs. Delayed recognition can lead to symptomatic hyponatremia with consequent cerebral edema and possibly irreversible neurological damage. Symptoms and signs of hyponatremia may be subtle or not attributed to hyponatremia. Most cases are of the euvolemic type, in which extracellular fluid volume is normal and is often due to the syndrome of inappropriate secretion of antidiuretic hormone. Hyponatremia can also occur in association with hypervolemia or hypovolemia. Common to all of these circumstances is increased secretion of arginine vasopressin (AVP). Understanding of the pathophysiological basis of hyponatremia and of brain compensatory mechanisms is critical to safe treatment. Fluid restriction or infusion of hypertonic saline can improve symptoms and normalize serum sodium levels but does not address excess AVP, which in most cases is the underlying cause of the disorder. A major new approach to treatment of hyponatremia is the development of aquaretics: AVP-receptor antagonists that provide a targeted therapeutic approach to correcting the many kinds of hyponatremia caused by excess AVP levels.
Keywords
antidiuretic hormone; aquaretics; arginine vasopressin (AVP); hyponatremia; SIADH; paroxetine-induced hyponatremia; diuretic-induced hyponatremia; serum; sodium concentration; healthy elderly men; inappropriate secretion; antidiuretic-hormone; water homeostasis; risk-factors; symptomatic; hyponatremia; aldosterone system
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity